154 research outputs found
Ultrasound-integrated tight control in early psoriatic arthritis during adalimumab treatment
Contributo scientific
Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis
Twelve dogs naturally infected with Leishmania infantum were treated subcutaneously with aminosidine at a dose of 10 mg kg(-1) per day for four weeks, Antimonial compounds were used as reference drugs in twelve Leishmania-infected dogs. Eleven of the twelve dogs submitted to aminosidine therapy responded within 30 days. The treatment with the aminoglycoside antibiotic presented a marked decrease of anti-Leishmania antibody titres than the controls. Aminosidine also reduced urinary protein, serum IgG, and circulating immune complex concentrations. Side effects were observed only in a dog with pre-existent renal lesions, This study proved that aminosidine is an effective, tolerable and safe drug for the treatment of canine leishmaniasis and that it could be used as a suitable substitute for antimonial therapy. (C) 1997 Published by Elsevier Science B.V
Figures 99-100 in Notes on the tiger beetles (Coleoptera: Cicindelidae) of Argentina. 117. Contribution towards the knowledge of Cicindelidae
Figures 99-100. Habitat pictures, taken by the second author. 99) Buenos Aires, Laguna de Gomez, c/o Junin, 14.xii.2011, collection site of Cylindera (Plectographa) melaleuca melaleuca and Cylindera (Plectographa) apiata apiata. 100) Santiago del Estero, Nueva Esperanza, 24.xii.2011, collection site of Tetracha (Neotetracha) fulgida, Tetracha (Neotetracha) pseudodistinguenda, Tetracha (Neotetracha) distinguenda and Cylindera (Plectographa) ritsemae.Published as part of Wiesner, Jürgen & Bandinelli, Aligi, 2014, Notes on the tiger beetles (Coleoptera: Cicindelidae) of Argentina. 117. Contribution towards the knowledge of Cicindelidae, pp. 1-66 in Insecta Mundi 2014 (377) on page 51, DOI: 10.5281/zenodo.517936
Indagini immunoistochimiche su un tumore primario prostatico a cellule fusate in un cane
Abitare a Ravenna: Le domus di Via D'Azeglio
Video relativo alla mostra Abitare a Ravenna. Le domus di via d'Azeglio, elaborato in occasione del III Convegno internazionale del CISEM
The Italian version of the Hand Mobility in Scleroderma (HAMIS) test: evidence for its validity and reliability
OBJECTIVES:
In systemic sclerosis (SSc), hand involvement is frequent and leads to prominent disability. The Hand Mobility in Scleroderma (HAMIS) test is a hand function test for SSc patients assessing the movements included in an ordinary range of motion examination. Our aim is to validate the Italian version of HAMIS, by assessing its test-retest reliability, internal consistency and external consistency in Italian SSc patients.
METHODS:
The Italian version of HAMIS was administered to 40 SSc patients. HAMIS was translated according to international procedures. Test-retest reliability was assessed by intra-class correlation coefficient (ICC), internal consistency by Cronbach's alpha and external consistency by comparison with Cochin Hand Function Scale (CHFS), fist closure, hand opening, HAQ.
RESULTS:
HAMIS showed a good testretest reliability (ICCs=0.99 for right and left hand) and internal consistency (Cronbach's α=0.94 for right and 0.93 for left hand) for both hands. A good external consistency was confirmed by the correlation of right and left hand HAMIS with CHFS (p<0.0001, in both cases); fist closure of homolateral hand (p<0.0001 in both cases), opening of homolateral hand (p<0.05 and <0.005, respectively), HAQ (p<0.001 in both cases). HAMIS scores for right and left hands were 7.95±6 .68 and 7.5±6.60 (p=NS), respectively. HAMIS scores for both hands were higher in dSSc and in patients with hand arthritis and flexion contractures.
CONCLUSIONS:
HAMIS is a hand function test measuring hand disability in SSc. Our results support its validity and reliability in Italian SSc patients
Low frequency analysis of multi-scale problems with a multi-resolution clipping technique
Insights Into Late-Onset Rheumatoid Arthritis (LORA): Characteristics (Clinical and Imaging), Comorbidities, and Therapeutic Targets
Late-onset rheumatoid arthritis (LORA) is defined as rheumatoid arthritis (RA) manifesting after the age of 65 years, although the terminology remains somewhat ambiguous. With the advent of a super-aging society and extended life expectancies, a significant increase in the incidence of LORA is anticipated. In comparison to young-onset RA (YORA), LORA is predominantly characterized by a higher incidence of acute onset, augmented disease activity and constitutional symptoms, a propensity for systemic manifestations, increased erythrocyte sedimentation rate at disease onset, reduced seropositivity, a predilection for involvement of large and proximal joints with symptoms resembling polymyalgia rheumatica, a higher frequency of erosive disease, and a more evenly distributed gender ratio. Elderly individuals, particularly those with multimorbidity and on multiple medications (polypharmacy), are at an elevated risk of developing geriatric syndromes, including sarcopenia and frailty. The response to TNF inhibitors in elderly individuals with RA is generally comparable to that in younger patients, though it may be slightly diminished. The duration of the disease appears to have a more pronounced impact on outcomes than the patient's age. For the management of LORA, it is critical to adopt a patient-specific approach. Non-frail LORA patients who are otherwise aging healthily should receive aggressive treat-to-target management. Conversely, in pre-frail and frail patients, the therapeutic focus should be on averting the progression of irreversible geriatric conditions. The confluence of multimorbidity, polypharmacy, and geriatric syndromes in this patient population necessitates a tailored therapeutic approach to maintain patient autonomy and functional status
Incremental Multilevel Filling and Sparsification for the MoM Solution of Multi-Scale Structures at Low Frequencies
- …
